مباشر

Endpoints NewsAfter an apparent cure, a gene editing company struggles to repeat the magic Endpoints NewsTakeda to target 4,500 jobs as incoming CEO continues restructuring Clinical OMICsPersonalized DNA Vaccine Shows Immune Activation and Survival Signals in Glioblastoma Trial Clinical OMICsAberrant Splicing Patterns Could Predict Therapy Response in mRCC Clinical OMICsRate of New Late-Stage Breast Cancers Increases FierceBiotechIcon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities Endpoints NewsValneva to cut up to 15% of jobs as reduced travel hits vaccine demand WatersWaters Corporation stock (US9418481035): Analytical instruments leader for US life sciences - AD HOC NEWS BioPharma DiveFDA’s leadership void leaves biotech with renewed ‘uncertainty’BioWorldUp to BAT in PSC, Mirum base case proven with phase IIb Endpoints NewsAbeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3 BioPharma DiveLilly data point to ‘maintenance’ strategies for GLP-1 weight loss

Endpoints News ١٣ مايو ٢٠٢٦

Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3

Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid...

Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech, which is known for marketing the rare ...